A bold insight into blood lipids reveals new angles for understanding and tackling early primary biliary cholangitis (PBC).
Researchers across several Polish medical centers conducted a detailed analysis of plasma sphingolipid profiles in 45 patients with early-stage PBC who were receiving standard ursodeoxycholic acid therapy, comparing them to 30 healthy controls. Using cutting-edge Ultra-High-Performance Liquid Chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS), the study delineated a distinctive pattern of sphingolipid disruption that appears closely linked with inflammation, immune balance, and early fibrotic changes in the liver.
Key sphingolipid shifts in early PBC
- A broad drop in total sphingolipid levels characterized the PBC group, with particularly notable decreases in phosphorylated lipids such as sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (SPA1P). These lipids are known to influence immune regulation and vascular function.
- The reductions correlated with portal hemodynamic abnormalities measured by Doppler ultrasound, suggesting a potential role for sphingolipids in the vascular disturbances common to cholestatic liver disease.
Ceramide alterations spotlight disease activity
- In contrast, levels of the C18:1-ceramide subtype were elevated in individuals with PBC and tended to align with greater liver stiffness, a marker associated with worsening fibrosis.
- Very-long-chain ceramides, which can play protective metabolic roles, were found to be reduced in the PBC group.
Links to inflammation and immune signaling
- The study identified meaningful associations between lipid disturbances and inflammatory markers. For instance, sphingosine levels showed a positive correlation with interleukin-6, a cytokine integral to chronic inflammation and autoimmune processes. This supports the view that sphingolipids may actively participate in the immune dysregulation and tissue remodeling characteristic of PBC, rather than merely reflecting downstream changes.
Implications and future directions
- The authors propose that early PBC exhibits a selective, disease-specific sphingolipid signature. While additional research is necessary to validate these findings, the results raise the possibility that certain sphingolipids could serve as biomarkers of disease activity or even as therapeutic targets, offering a new perspective for diagnosing and treating cholestatic liver disorders.
Reference
Rogalska M et al. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep. 2025; 15:42502.
Author note:
Each article is distributed under the Creative Commons Attribution-Non Commercial 4.0 License.
